TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.
Cohort (n=28,805)
Yes
Does TF-TAVR improve in-hospital outcomes and cost-effectiveness compared to SAVR in younger patients?
Younger patients undergoing aortic valve replacement
Transfemoral transcatheter aortic valve replacement (TF-TAVR)
Surgical aortic valve replacement (SAVR)
In-hospital outcomes and cost-effectiveness
A shift from SAVR to TF-TAVR in younger patients appears to be cost-effective with justifiable incremental costs per life saved.
Effect estimate: RR 0.65
Absolute Event Rate: 1.7% vs 1.6%
p-value: p=0.012
Given an estimated life expectancy of 11 to 25 years in this population, the incremental costs per life saved associated with a hypothetical shift from SAVR to TF-TAVR appear justifiable. Nonetheless, individual patient circumstances must always be considered in decision-making.
Building similarity graph...
Analyzing shared references across papers
Loading...
Klaus Kaier
C. Von Zur Mühlen
University of Freiburg
Derek Hazard
University of Freiburg
Clinical Research in Cardiology
University of Freiburg
University Medical Center Freiburg
Universitäts-Herzzentrum Freiburg-Bad Krozingen
Building similarity graph...
Analyzing shared references across papers
Loading...
Kaier et al. (Mon,) conducted a cohort in Severe aortic stenosis (n=28,805). Transfemoral transcatheter aortic valve replacement (TF-TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on In-hospital mortality (RR 0.65, p=0.012). TF-TAVR significantly reduced in-hospital mortality (RR 0.65) compared to SAVR in patients aged 60-75 with severe aortic stenosis, though it was associated with higher reimbursement costs.
synapsesocial.com/papers/69df2bece4eeef8a2a6b0d58 — DOI: https://doi.org/10.1007/s00392-026-02911-9